Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab's Partner Approved for US Launch of Myasthenia Gravis Therapy

publication date: Dec 21, 2021

Shanghai Zai Lab announced that its partner argenx SE was approved for a US launch of its myasthenia gravis therapy. Vyvgart™ (efgartigimod alfa-fcab) was approved to treat generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. About 85% of gMG patients are AChR antibody positive. In January 2021, Zai in-licensed China rights to Vyvgart in a $175 million agreement, including a $70 upfront payment. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688) (Euronext/NSDQ: ARGX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.